⌘K

16:42:32·1210d

PRReleasevia Quantisnow

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

ByQuantisnow·Wall Street's wire, on your screen.

EBS· Emergent BioSolutions Inc.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 694 shares, decreasing direct ownership by 0.43% to 162,098 units (SEC Form 4)
EVP, Chief Financial Officer Lindahl Richard S covered exercise/tax liability with 3,964 shares, decreasing direct ownership by 1% to 374,083 units (SEC Form 4)
EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 2,018 shares, decreasing direct ownership by 0.99% to 202,201 units (SEC Form 4)
SVP, Bioservices Hartzel William covered exercise/tax liability with 1,741 shares, decreasing direct ownership by 0.93% to 185,558 units (SEC Form 4)
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose